8-K: Henry Schein Reports Mixed Q2 Results, Updates Full-Year Guidance Amidst Cyber Incident Recovery

Henry Schein reported a 1.1% increase in second-quarter sales but lowered its full-year guidance due to a slower-than-expected recovery from a cyber incident and challenging economic conditions.

Summary

• Henry Schein's second-quarter 2024 net sales reached $3.1 billion, a 1.1% increase compared to the same period last year.
• The company's internal sales decreased by 2.4%, which includes a 0.5% decrease from lower PPE sales.
• GAAP net income for the quarter was $104 million, or $0.80 per diluted share, down from $140 million, or $1.06 per diluted share, in the second quarter of 2023.
• Non-GAAP net income for the quarter was $158 million, or $1.23 per diluted share, compared to $173 million, or $1.31 per diluted share, in the prior year.
• Operating cash flow for the quarter was $296 million, up $22 million compared to the second quarter of 2023.
• The company's year-to-date operating cash flow was $493 million, a $192 million increase compared to the same period in 2023.
• A new restructuring plan is targeting $75 million to $100 million in annual run-rate savings.
• The company has updated its full-year 2024 non-GAAP EPS guidance to $4.70 to $4.82, down from the previous guidance of $5.00 to $5.16.
• Full-year 2024 total sales growth is now expected to be approximately 4% to 6%, compared to the prior guidance of 8% to 10%.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative due to lowered guidance, slower recovery from the cyber incident, and decreased earnings. However, the restructuring plan and increased share repurchase authorization provide some positive aspects.

Positives

• Operating cash flow showed strong growth, with a $22 million increase in the second quarter and a $192 million increase year-to-date compared to 2023.
• Gross margin continued to increase due to strategies to expand high-growth, high-margin products and services and successful acquisitions.
• The company is implementing a new restructuring plan targeting significant annual cost savings.
• The share repurchase program has been increased by $500 million, indicating confidence in the company's future.
• Global Technology and Value-Added Services showed strong growth with a 10.8% increase in sales for the quarter and 12.3% year to date.

Negatives

• The pace of recovery in the distribution businesses since the cyber incident has been slower than anticipated.
• The company has lowered its full-year 2024 financial guidance for both sales growth and non-GAAP diluted EPS.
• GAAP net income and diluted EPS decreased significantly compared to the same period last year.
• Internal sales decreased by 2.4% for the quarter and 2.1% year to date.
• Adjusted EBITDA for the first half of 2024 was $523 million, down from $535 million in the first half of 2023.

Risks

• The company is facing challenges in recovering from a cyber incident that occurred late last year.
• The challenging economic environment in certain markets is impacting the company's performance.
• The company is experiencing lower sales of personal protective equipment (PPE), primarily due to lower glove pricing.
• The company's restructuring plan may involve significant charges in the second half of 2024 and in 2025.
• The company's future performance is subject to various risks and uncertainties, including dependence on third-party suppliers, competition, and regulatory changes.

Future Outlook

The company has updated its full-year 2024 financial guidance, expecting total sales growth of approximately 4% to 6% and non-GAAP diluted EPS of $4.70 to $4.82. Adjusted EBITDA is expected to grow in the low double-digit percentages versus 2023. These figures are lower than previous guidance due to a slower recovery from a cyber incident and challenging economic conditions.

Management Comments

• We delivered solid second quarter financial results, including strong operating cash flow, that reflected stable end markets.
• Gross margin continued to increase, driven by our strategies to expand our high-growth, high-margin products and services and by the successful performance of our recent acquisitions.
• We are experiencing improving sales trends in our distribution businesses, however, the pace of recovery in these businesses since the cyber incident late last year has been slower than anticipated.
• Given the challenging economic environment in certain markets, as well as this delay in recovery from the cyber incident, we are updating our 2024 full-year financial guidance.
• We remain committed to our long-term financial goals through advancement of the BOLD+1 Strategic Plan, supported by our strong balance sheet and new restructuring plan, as we continue to generate synergies by connecting our distribution businesses, specialty products, and technology and value-added services.

Industry Context

This announcement comes at a time when the healthcare industry is facing various challenges, including economic uncertainty and cybersecurity threats. Henry Schein's results reflect these broader trends, with the cyber incident impacting their recovery and the economic environment affecting their sales growth. The company's focus on restructuring and cost savings is a common response to these challenges in the industry.

Comparison to Industry Standards

• Henry Schein's 1.1% sales growth in Q2 2024 is below the average growth rate for medical and dental supply companies, which have seen growth rates between 3% and 7% in recent quarters.
• Companies like Patterson Companies (PDCO) and McKesson (MCK) have reported stronger sales growth in their respective segments, indicating that Henry Schein's recovery from the cyber incident is lagging behind industry peers.
• The updated full-year EPS guidance of $4.70 to $4.82 is also below the average analyst estimates for the sector, which were closer to the $5.00 to $5.16 range before the guidance revision.
• The restructuring plan targeting $75 million to $100 million in annual savings is similar to cost-cutting measures being implemented by other companies in the healthcare distribution sector to improve profitability.
• The increase in share repurchase authorization by $500 million is a positive sign, but it is not uncommon for companies in this sector to use share repurchases to return value to shareholders.

Stakeholder Impact

• Shareholders will be impacted by the lowered financial guidance and decreased earnings, but may be positively influenced by the increased share repurchase program.
• Employees may be affected by the restructuring plan, which includes potential severance pay and facility-related costs.
• Customers may experience some disruption due to the cyber incident recovery, but the company is working to improve its services.
• Suppliers may be impacted by the company's restructuring efforts and changes in purchasing patterns.
• Creditors may be affected by the company's updated financial outlook and restructuring plan.

Next Steps

• The company will hold a conference call to discuss second-quarter 2024 financial results.
• The company will record restructuring charges in the second half of 2024 and in 2025.
• The company will continue to implement its BOLD+1 Strategic Plan.
• The company will continue to execute its share repurchase program.

Key Dates

Keywords

Henry Schein, financial results, earnings, cyber incident, restructuring, share repurchase, healthcare solutions, dental, medical, technology, EBITDA, EPS, sales growth